Skip Navigation


European Heart Journal Advance Access originally published online on May 5, 2007
European Heart Journal 2007 28(10):1180-1181; doi:10.1093/eurheartj/ehm155
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/10/1180    most recent
ehm155v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Joseph, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joseph, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

The stem cell army in heart failure: do we mobilize or pave the way home?

Jacob Joseph1,2,

1 Cardiology Section (111), VA Boston Healthcare System, 1400 VFW Parkway, West Roxbury, MA 02132, USA
2 Boston University School of Medicine, Boston, MA, USA

Corresponding author. Tel: +1 857 203 6841; fax: +1 857 203 5550. E-mail address: jacob.joseph@med.va.gov

This editorial refers to ‘Circulation of CD34+ progenitor cell populations in patients with idiopathic dilated and ischaemic cardiomyopathy (DCM and ICM)’{dagger} by H.D. Thiess et al., on page 1258

The first 10% of the full text of this article appears below.

Pharmacological modulation of heart failure, although capable of substantially reducing morbidity and mortality, does not halt the relentless progression of adverse cardiac remodelling and failure. Hence, invoking the body's own repair mechanisms embodied in its stem cell population present in the myocardium itself or mobilized from the bone marrow is an attractive therapeutic concept to combat heart failure. Pre-clinical studies have shown the promise of this therapy1; however, much work needs to be done to address various questions that arise about bone marrow-derived stem cells in regard to mobilization, homing to the myocardium, their fate within the myocardium, and whether mechanism of benefit is due to regeneration of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Circulation of CD34+ progenitor cell populations in patients with idiopathic dilated and ischaemic cardiomyopathy (DCM and ICM)
Hans D. Theiss, Robert David, Markus G. Engelmann, Andreas Barth, Klaus Schotten, Michael Naebauer, Bruno Reichart, Gerhard Steinbeck, and Wolfgang-M. Franz
EHJ 2007 28: 1258-1264. [Abstract] [FREE Full Text]